Grepafloxacin in respiratory tract infections: Are we ready to accept a quinolone for empirical treatment?

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue SUPPL. A, 1997, Pages 99-101

  Norrby, S Ragnar ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GREPAFLOXACIN; QUINOLONE;

ANTIBIOTIC RESISTANCE; ARTHROPATHY; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; INSOMNIA; NONHUMAN; PHOTOTOXICITY; RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0031445107     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.suppl_1.99     Document Type: Conference Paper

References (12)

1. Imada, T., Miyazaki, S., Nishida, M., Yamaguchi, K. & Goto, S. (1992). In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrobial Agents and Chemotherapy 36, 573-9.
2. Wiedemann, B. (1997). In vitro activity of grepafloxacin. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 00-00.
3. Wise, R. & Andrews, J. M. (1997). The activity of grepafloxacin against respiratory pathogens in the UK. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 27-30.
4. Ridgway, G. L., Salman, H., Robbins, M. J., Dencer, C. & Felmingham, D. (1997). The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 31-34.
5. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy 35, 230-1.
6. Efthymiopoulos, C. (1997). Pharmacokinetics of grepafloxacin. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 35-43.
7. Forrest, A., Chodosh, S., Amantea, M. A., Collins, D. A. & Schentag, J. J. (1997). Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 45-57.
8. Pan, X.-S. & Fisher, L. M. (1997). Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrobial Agents and Chemotherapy 45, 471-4.
9. Norrby, S. R. & Lietman, P. S. (1993). Safety and tolerability of fluoroquinolones. Drugs 45, Suppl. 3, 59-64.
10. Stahlmann, R. & Schwabe, R. (1997). Safety profile of grepafloxacin compared with other fluoroquinolones. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 83-92.
11. Ferguson, J. & Dawe, R. (1997). Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 93-98.
12. Nordic Atypical Pneumonia Study Group. (1997). Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Journal of Antimicrobial Chemotherapy 39, 499-508.